Leukemia

Researchers have shown that mycophenolate mofetil accelerates neutrophil engraftment compared to methotrexate in cord blood transplantation.

Data from a phase 2 trial show that quizartinib plus omacetaxine mepesuccinate may better position patients to proceed to consolidative transplantation.

Investigators are assessing CLN-049 among patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome in a phase 1 study.

Data from the phase 1/2 ASTX727-07 study support the FDA approval of decitabine plus cedazuridine and venetoclax in this AML population.

The ASPHO Conference brings together the world’s leading experts in pediatric oncology and hematology, and this collection of posters detail new findings in care.

Investigators are on track to complete the phase 1b dose-escalation portion of the RAINIER trial in 2026.

New developments revealed regulatory milestones for bacterial therapeutic candidates and potential efficacy with vaccine-based approaches.

Hematologic oncologists discussed long-term survival data from the SEQUOIA and ALPINE trials exploring zanubrutinib in frontline and R/R CLL/SLL.

Data from the phase 1/2 CARDINAL trial support the breakthrough therapy designation for TERN-701 in this chronic myeloid leukemia population.

Orca-T has demonstrated clear benefits in reducing graft-vs-host disease among patients with hematologic malignancies, according to Wendy Stock, MD.

Although not yet mature, overall survival data trended in favor of pirtobrutinib plus venetoclax/rituximab in the phase 3 BRUIN CLL-322 trial.

Newer generations of BTK inhibitors may have fewer cardiac toxicities compared with earlier iterations, according to Nicole Lamanna, MD.

Experts from Columbia University highlight approvals in CLL, bispecific antibodies in multiple myeloma, and actionable biomarkers in DLBCL.

Acalabrutinib/venetoclax may offer less toxicity compared with other therapies in chronic lymphocytic leukemia, said Nicole Lamanna, MD.

No patients with frontline acute myeloid leukemia experienced cytokine release syndrome following treatment with mipletamig plus venetoclax/azacitidine.

Preliminary findings have shown an “unprecedented” result with blinatumomab in mixed phenotype acute leukemia, according to Ashkan Emadi, MD, PhD.

Data from the phase 3 Precision-T trial show improvements in overall survival and relapse-free survival with the use of Orca-T.

A phase 2 trial in mixed phenotype acute leukemia shows that “big things” can happen regardless of where patients live or the rarity of their diseases.

Frontline acalabrutinib tablets have been approved by the FDA for the treatment of CLL and SLL.

A phase 2 trial will determine whether subcutaneous blinatumomab can offer benefit to a patient population with no other treatment options.

New guidelines highlight asparaginase as a cornerstone of frontline therapy for adolescents and young adults with acute lymphoblastic leukemia.

Older age appeared to correlate with worse survival among those undergoing allogenic hematopoietic cell transplantation for acute lymphoblastic leukemia.

No serious adverse effects were observed with TRX103 in patients with hematologic malignancies undergoing HLA-mismatched HCT.

An unadjusted indirect comparison analysis of the SEQUOIA and AMPLIFY trials revealed improved PFS with zanubrutinib vs acalabrutinib plus venetoclax.